We identified NRAS Q61R/K/L mutations in 14 canine tumors, 57% (8/14) of which were hemangiosarcoma, 28% (4/14) malignant melanoma, 7% (1/14) plasma cell tumors and 7% (1/14) soft tissue sarcoma (Table S5). This evidence concerns the gene NRAS and melanoma.